Elemery Monika, Kiss Szilvia, Dome Peter, Tombor Laszlo, Faludi Gabor, Lazary Judit
Pszichiátriai és Pszichoterápiás Klinika, Semmelweis Egyetem, Budapest, Hungary.
Neuropsychopharmacol Hung. 2019 Dec;21(4):179-186.
There is a 20-year history of rTMS treatment, however, is not available in Hungary in routine clinical practice for therapy resistant depression (TRD). In this study we analysed the change of symptom profile of a Hungarian cohort with TRD using bilateral rTMS treatment.
A cohort of 22 patients suffering from TRD was enrolled in the study. For assessment of the phenotypic profile the Beck Depression Inventory (BDI), The Beck Anxiety Inventory (BAI), The Montgomery-Asberg Depression Rating Scale (MADRS), the Snaith-Hamilton Pleasure Scale (SHAPS), the Insomnia Severity Index (ISI), and the Trail Making Test were applied. Differences of mean scores of scales were compared between the day 1 (before treatment) and the day 14 (after conclusion of treatment). Furthermore, we performed phenotypic comparisons between the gender subgroups.
In the total sample significant reduction of symptom scores was found on the depression (pMADRS=0,022; pBDI=0,001) and the anxiety scales (pBAI=0,020) and in case of the TMT-A test (pTMT-A=0,019) at the end of the treatment. The mean scores of the SHAPS, the ISI and the TMT-B did not change up to the day 14. In the sex-specific analysis we found that in men only sleep disorder was improved (p=0,015), while in women both depression scores and TMT-A score decreased significantly (MADRSp=0,015; BDIp=0,005; TMT-Ap=0,036). There were no adverse events during the rTMS treatment.
2x5 sessions of bilateral rTMS treatment is an effective, safety applicable intervention in patients with TRD. Our results suggest that significant improvement of depressive, anxious and attention symptoms can be observed already after 10th session. Our findings highlighted that different symptoms evolve in women and men due to the acute effect of the rTMS treatment. Further follow-up study is required to evaluate the long-term effect of rTMS concerning the maintenance of symptom reduction and potential change of anhedonia and insomnia.
重复经颅磁刺激(rTMS)治疗已有20年历史,但在匈牙利,它在常规临床实践中尚未用于治疗难治性抑郁症(TRD)。在本研究中,我们分析了使用双侧rTMS治疗的匈牙利TRD队列患者症状特征的变化。
本研究纳入了22例患有TRD的患者。为评估表型特征,应用了贝克抑郁量表(BDI)、贝克焦虑量表(BAI)、蒙哥马利-艾斯伯格抑郁评定量表(MADRS)、斯奈斯-汉密尔顿愉悦量表(SHAPS)、失眠严重程度指数(ISI)和连线测验。比较了第1天(治疗前)和第14天(治疗结束后)量表平均得分的差异。此外,我们还对性别亚组进行了表型比较。
在整个样本中,治疗结束时抑郁量表(pMADRS = 0.022;pBDI = 0.001)、焦虑量表(pBAI = 0.020)以及连线测验A部分(pTMT-A = 0.019)的症状得分显著降低。直至第14天,SHAPS、ISI和连线测验B部分的平均得分未发生变化。在性别特异性分析中,我们发现仅男性的睡眠障碍得到改善(p = 0.015),而女性的抑郁得分和连线测验A部分得分均显著降低(MADRS p = 0.015;BDI p = 0.005;TMT-A p = 0.036)。rTMS治疗期间未出现不良事件。
2×5次双侧rTMS治疗是一种对TRD患者有效且安全适用的干预措施。我们的结果表明,在第10次治疗后即可观察到抑郁、焦虑和注意力症状的显著改善。我们的研究结果强调,由于rTMS治疗的急性效应,女性和男性的不同症状会有所变化。需要进一步的随访研究来评估rTMS在维持症状减轻以及快感缺失和失眠潜在变化方面的长期效果。